How do you counsel a patient with breast cancer and a rad50 mutation when deciding between lumpectomy and radiation vs mastectomy?

There are currently no data suggesting that a heterozygous RAD50 mutation is associated with increased clinical risk of radiation toxicity and I would not alter treatment options based on this information. While it is a DNA repair molecule, this does not de facto indicate a risk for radiotherapy. BRCA is a commonly detected DNA repair molecule that is not associated with increased risk of radiation toxicity. Given the increasing detection of mutations of uncertain significance for radiotherapy, ...